Inflation-Adjusted Prices for US Brand-Name Prescription Drugs Declined for Seventh Consecutive Year in 2024

Inflation-adjusted prices for U.S. brand-name prescription drugs declined for the seventh consecutive year in 2024, according to recent data. The average list price of brand-name medications increased by just 2.3% last year, while net prices—those adjusted for inflation and accounting for rebates and discounts—continued their downward trend. This marks a significant shift in drug pricing dynamics, influenced by legislative changes, industry strategies, and evolving market models.

Key factors contributing to this trend include the Inflation Reduction Act (IRA), modifications to Medicaid rebate policies, and innovative formulary access strategies adopted by manufacturers. Some pharmaceutical companies have implemented direct list-price reductions on high-rebate products, with at least 18 such cases identified. Others have slowed the rate of price increases, further easing upward pressure on overall costs. Meanwhile, emerging distribution models such as smaller pharmacy benefit managers (PBMs), cost-plus pharmacies, patient-paid discount cards, and direct-to-patient sales channels are reshaping how drugs reach consumers without relying on traditional gross-to-net pricing structures.

The extent to which insured patients benefit from these changes depends largely on decisions made by employers, health plans, and PBMs regarding cost-sharing arrangements. While the so-called “gross-to-net bubble” remains intact for now, signs point to gradual shifts in conventional pricing approaches within the pharmaceutical supply chain.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: April 4, 2025

Related posts:

O’Neill, HHS Nominee, Financial Disclosures Show Prior Work With Vaccine Companies. Eli Lilly to lead oligonucleotide therapy development in new collaboration Proposed Import Tariffs on Pharmaceutical Goods Could Reshape US Supply Chains High-Fiber Plant-Based Diet Shows Potential in Delaying Progression of Precancerous Conditions Linked to Multiple Myeloma

Author

Mark Chiang